Spiriva Respimat (Tiotropium) Gets Asthma Indication in US – Medscape


European Pharmaceutical Review

Spiriva Respimat (Tiotropium) Gets Asthma Indication in US
Medscape
The US Food and Drug Administration (FDA) has approved the long-acting muscarinic antagonist tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim) for long-term maintenance treatment of asthma in people aged 12 years and older, according to a …
FDA approves Boehringer's asthma treatmentWestfair Online
FDA approves asthma treatment Spiriva RespimatEuropean Pharmaceutical Review

all 3 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.